A High-Throughput Cell-based Drug Discovery System
高通量细胞药物发现系统
基本信息
- 批准号:6885328
- 负责人:
- 金额:$ 64.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-06-15 至 2007-04-30
- 项目状态:已结题
- 来源:
- 关键词:apoptosisbioengineering /biomedical engineeringbiomedical automationbiomedical equipment developmentbiotechnologycell mediated lymphocytolysis testchemical registry /resourcecomputer program /softwaredrug discovery /isolationdrug screening /evaluationgene expression profilinghigh throughput technologymethod developmentmicroarray technologyminiature biomedical equipmentpharmacokinetics
项目摘要
DESCRIPTION (provided by applicant): This Phase II SBIR project is focused at the development of a high-throughput screening method and instrument for drug discovery using miniaturized, cell-based assays. For developing new drugs against complex diseases such as diabetes, cancer and neurological and cardiovascular disorders, high throughput screening using cell-based assays will be essential. Miniaturization of cell-based assays for automation and reduced costs is required. GeneCard-HTS enables drug discovery using adherent cell-based assays. During the Phase I project, the feasibility of the GeneCard approach was demonstrated using apoptosis assays. A prototype instrument to automate GeneCard assay process was developed and assembled. During Phase II, the versatility and flexibility of the GeneCard platform will be investigated by performing other cell-based assays used in drug discovery. The proposed plan investigates the following three specific aims:
1. Build a high-throughput screening prototype system based on GeneCard technology (GeneCard-HTS).
2. Miniaturize multiple cell-based assays for GeneCard-HTS platform. We will miniaturize four commonly used drug discovery assays in the GeneCard-HTS platform, i) Apoptosis assays using the Mitosensor reagents, ii) cell-based kinase assays, iii) fluorescent cytotoxicity assays, and iv) gene expression profiling assays. We will measure the performance of these assays in GeneCard-HTS platform and compare with performance obtained at present.
3. Validate GeneCard-HTS by cell-based screening of compound libraries. In order to validate the Genecard-HTS system, we will perform screening of a 5,000 compound focused library using cell-based kinase and apoptosis assays. We will measure validation parameters such as system lifetime, operating temperature and humidity range, inter- and intra- assay variability, and day-to-day variability.
Commercial applications of the proposed system include pharmaceutical and biotechnoiogy drug discovery. Further integration of the instrument based on design specifications prepared in Phase I will be performed. Screening of drug compound libraries to identify potential lead compounds will be performed.
描述(由申请人提供):此II期SBIR项目的重点是开发使用基于细胞的小细胞测定法的高通量筛查方法和用于药物发现的仪器。对于针对糖尿病,癌症和神经系统和心血管疾病等复杂疾病的新药,使用基于细胞的测定的高吞吐量筛查至关重要。基于细胞的自动化和降低成本的小型化。 Genecard-HTS可以使用基于细胞的测定方法来发现药物。在I阶段项目中,使用凋亡测定法证明了Genecard方法的可行性。开发并组装了一种自动化Genecard分析过程的原型仪器。在II阶段期间,将通过执行用于药物发现中的其他基于细胞的测定法来研究Genecard平台的多功能性和灵活性。拟议的计划调查了以下三个具体目标:
1。建立基于GeneCard技术(Genecard-HTS)的高通量筛选原型系统。
2。对Genecard-HTS平台的多个基于细胞的测定。我们将在Genecard-HTS平台中的四个常用药物发现测定法,i)使用Mitosensor试剂的凋亡测定,ii)基于细胞的激酶测定,iii)荧光细胞毒性测定和IV)基因表达分析分析测定法。我们将在Genecard-HTS平台中衡量这些测定的性能,并与目前获得的性能进行比较。
3。通过基于细胞的化合物库来验证Genecard-HT。为了验证Genecard-HTS系统,我们将使用基于细胞的激酶和凋亡测定法对5,000个复合库进行筛选。我们将衡量验证参数,例如系统寿命,工作温度和湿度范围,间和内分析变异性以及日常变异性。
拟议系统的商业应用包括药物和生物技术学药物发现。将根据第I期准备的设计规范进一步整合仪器。将进行药物化合物文库筛选以鉴定潜在的铅化合物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rajan Kumar其他文献
Rajan Kumar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rajan Kumar', 18)}}的其他基金
LFIA: A Microfluidic Protein Interaction Analysis Method
LFIA:一种微流控蛋白质相互作用分析方法
- 批准号:
6935653 - 财政年份:2005
- 资助金额:
$ 64.4万 - 项目类别:
Microfluidics Laminar Flow Endothelial Cell Assays
微流体层流内皮细胞分析
- 批准号:
6644644 - 财政年份:2003
- 资助金额:
$ 64.4万 - 项目类别:
A High-Throughput Cell-based Drug Discovery System
高通量细胞药物发现系统
- 批准号:
6485791 - 财政年份:2002
- 资助金额:
$ 64.4万 - 项目类别:
A High-Throughput Cell-based Drug Discovery System
高通量细胞药物发现系统
- 批准号:
7065651 - 财政年份:2002
- 资助金额:
$ 64.4万 - 项目类别:
A High-Throughput Cell-based Drug Discovery System
高通量细胞药物发现系统
- 批准号:
6790833 - 财政年份:2002
- 资助金额:
$ 64.4万 - 项目类别:
REGULATION OF RHODOPSIN EXPRESSION--TRANS-ACTING FACTOR
视紫红质表达的调节--反式作用因子
- 批准号:
2160202 - 财政年份:1994
- 资助金额:
$ 64.4万 - 项目类别:
REGULATION OF RHODOPSIN EXPRESSION: TRANS-ACTING FACTOR
视紫红质表达的调节:反式作用因子
- 批准号:
2160201 - 财政年份:1993
- 资助金额:
$ 64.4万 - 项目类别:
REGULATION OF RHODOPSIN EXPRESSION: TRANS-ACTING FACTOR
视紫红质表达的调节:反式作用因子
- 批准号:
3039632 - 财政年份:1992
- 资助金额:
$ 64.4万 - 项目类别:
相似海外基金
NRI: Robotics to Improve Patient Care for Highly Infectious Diseases
NRI:机器人技术可改善高度传染病患者的护理
- 批准号:
9360113 - 财政年份:2016
- 资助金额:
$ 64.4万 - 项目类别:
NRI: Robotics to Improve Patient Care for Highly Infectious Diseases
NRI:机器人技术可改善高度传染病患者的护理
- 批准号:
9318658 - 财政年份:2016
- 资助金额:
$ 64.4万 - 项目类别:
Consensus Benchmarks, Interoperability & Quant. Assessment for Medical Robotics
共识基准、互操作性
- 批准号:
8785916 - 财政年份:2014
- 资助金额:
$ 64.4万 - 项目类别:
PROJECT 5 - DUKE - STRUCTURE VALIDATION AND IMPROVEMENT FOR PROTEINS AND N. ACIDS
项目 5 - DUKE - 蛋白质和核酸的结构验证和改进
- 批准号:
7208315 - 财政年份:2006
- 资助金额:
$ 64.4万 - 项目类别: